USING IMMUNE MARKERS TO INDIVIDUALISE THERAPY FOR PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER
Grant number: MCRF16022 | Funding period: 2019 - 2021
Related publications (4)
Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone
Katie L Owen, Linden J Gearing, Damien J Zanker, Natasha K Brockwell, Weng Hua Khoo, Daniel L Roden, Marek Cmero, Stefano Mangiola, Matthew K Hong, Alex J Spurling, Michelle McDonald, Chia-Ling Chan, Anupama Pasam, Ruth J Lyons, Hendrika M Duivenvoorden, Andrew Ryan, Lisa M Butler, John M Mariadason, Tri Giang Phan, Vanessa M Hayes
The latency associated with bone metastasis emergence in castrate-resistant prostate cancer is attributed to dormancy, a state in ..
Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma
Natasha K Brockwell, Muhammad Alamgeer, Beena Kumar, Gareth Rivalland, Thomas John, Belinda S Parker
Background: Malignant pleural mesothelioma (MPM) is well known as an aggressive disease with poor survival. This has sparked trial..
Intratumoral administration of the Toll-like receptor 7/8 agonist 3M-052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer
Damien J Zanker, Alex J Spurling, Natasha K Brockwell, Katie L Owen, Jasmine M Zakhour, Tina Robinson, Hendrika M Duivenvoorden, Paul J Hertzog, Stefanie R Mullins, Robert W Wilkinson, Belinda S Parker
Objectives: Loss of tumor-inherent type I interferon (IFN) signalling has been closely linked to accelerated metastatic progressio..